Company intelligence / Profile preview

Surfacide

Waukesha, Wisconsin, United States

Ownership: Private
Development stage: Other

Overview

Surfacide markets FDA-authorized Helios and Helios+ UV-C systems for whole-room microbial reduction as an adjunct to manual cleaning, with multiple peer-reviewed studies showing significant reductions in environmental bioburden and pathogens contributing to healthcare-associated and surgical site infections.[1][3][4][6]

Therapeutic areas: Infectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

RDB Bioinformatics (exclusive distribution partner for PathTrac clinical decision support software for operating-room infection prevention).[1]

Beyond the preview

Go deeper on Surfacide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surfacide.

Explore the full profile